Atosiban vs. ritodrine as a tocolytic in external cephalic version at term: a prospective cohort study.
J Perinat Med
; 38(1): 23-8, 2010.
Article
en En
| MEDLINE
| ID: mdl-20047524
ABSTRACT
OBJECTIVE:
To compare the success rate of external cephalic version (ECV) at term using ritodrine or atosiban as a tocolytic agent. STUDYDESIGN:
Prospective cohort study with a sample of 236 pregnant women with a breech presentation at term, from November 2006 to March 2008. Data have been analyzed from the moment the cephalic version is performed until the time of delivery.RESULTS:
ECV success rate using ritodrine as a tocolytic agent was 56.8% compared to 31.4% with atosiban. Ritodrine increases the version success potential more significantly than atosiban (P<0.05). In both cases, the use of ECV reduced the rate of cesarean sections, although a higher number of versions are required with atosiban [numbers needed to treat (NNT)=9.08] to avoid a cesarean section compared to ritodrine (NNT=3.41).CONCLUSIONS:
Ritodrine seems better than atosiban as tocolytic agent for ECVs.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ritodrina
/
Versión Fetal
/
Vasotocina
/
Tocólisis
/
Tocolíticos
Tipo de estudio:
Etiology_studies
/
Observational_studies
Límite:
Adult
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
J Perinat Med
Año:
2010
Tipo del documento:
Article
País de afiliación:
España